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OBJECTIVE: Hypertension, dyslipidemia, and diabetes, which
are established risk factors for cardiovascular disease (CVD),
have been previously described among adults aged 65 and older,
but have not been updated to reﬂect current national data. We
assess prevalence, awareness, treatment and control rates among
U.S. adults aged 65 and older with respect to hypertension,
dyslipidemia, and diabetes, and describe predictors associated
with awareness and management of these factors. METHODS:
Analysis of nationally representative data collected from adults
aged 65 and older (n = 3810) participating in the National
Health and Nutrition Examination Survey (NHANES) 1999–
2004. RESULTS: Women have a signiﬁcantly higher prevalence
of hypertension than men (76.6% vs 63.0%) and a signiﬁcantly
lower rate of control when treated pharmacologically (42.9% vs
57.9%). Dyslipidemia prevalence is 60.3% overall, and women
are signiﬁcantly more likely to be aware of their condition than
men (71.1% vs 59.1%). Diabetes affects 21.2% of older adults,
and 50.9% of prevalent cases are treated pharmacologically.
Goal attainment among those treated is problematic for all three
conditions–hypertension (48.8%), dyslipidemia (64.9%), and
diabetes (50.4%). Having two or more doctor visits annually is
associated with goal attainment for dyslipidemia. CONCLU-
SION: Knowledge of cardiovascular health in older adults and
understanding gender gaps in awareness can help physicians and
policymakers improve disease management and patient educa-
tion programs.
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OBJECTIVE: Guidelines and expert opinion regard the relation-
ship between low-density lipoprotein cholesterol (LDL-C) and
coronary heart disease (CHD) event rates fromprevention trials as
linear or log-linear. However, these relationships require key
assumptions that are typically invalid in biological systems, and
may be more fully described by a sigmoidal maximum effect
function.METHODS:Data were extracted from statin secondary
prevention trials of at least 4-years duration (CARE, LIPID, 4S,
HPS, TNT, IDEAL; N = 57,042; average duration 5.2 yrs, range
4.8–6.1 yrs). Linear and modiﬁed nonlinear sigmoid maximum
effect (sEmax) models were constructed using WinNONLIN
(v.1.5, Pharsight Corporation, Mountain View, CA) to evaluate
the relationship of annualized absolute rates of CHD death
plus nonfatal myocardial infarction (NFMI) versus average
on-treatment LDL-C. Model output included E0 (CHD
death + NFMI %/yr at LDL-C = 0 mg/dL) and ﬁt parameters [r2
and Akaike’s Information Criteria (AIC)]. The model-dependent
number needed to treat (NNT) for one year to prevent one CHD
death + NFMI event with LDL-C reduction from 100 mg/dL to
70 mg/dL was also calculated. RESULTS: Fit parameters indi-
cated that the sEmax was the more correct model (r2 = 0.906,
AIC = 8.40; linear r2 = 0.876, AIC = 15.99). The sEmax model
yielded an E0 of 1.37%/yr, whereas the linear model E0 was
biologically implausible at –0.76%/yr. The CHD death + NFMI
rate at LDL-C = 100 mg/dL (sEmax 1.91%/yr; linear 2.13%/yr)
and LDL-C = 70 mg/dL (sEmax 1.58%/yr; linear 1.14%/yr)
resulted in NNT of 303 and 101 based on sEmax and linear
models, respectively. CONCLUSION: The relationship between
LDL-C and annualized rate of CHD death + NFMI is sigmoidal
and best described by a nonlinearmaximum effectmodel (sEmax).
Thismodel demonstrates amarked diminishing rate of returnwith
aggressive LDL-C lowering, strongly suggesting alternative risk
modiﬁcation measures be explored at LDL-C <100 mg/dL. These
ﬁndings have clinical trial design, treatment guideline, managed
care, economic, and public health implications.
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OBJECTIVE: Clopidogrel is commonly co-prescribed with
aspirin in patients with heart disease, and therefore the associ-
ated risk of gastrointestinal adverse events may be high. We
sought to determine the incidence of medical claims for potential
gastrointestinal adverse events among clopidogrel users in an
administrative database. METHODS: Clopidogrel users were
identiﬁed in a large US database (representing a network of over
70 managed care plans) based on the following criteria: an initial
clopidogrel prescription between between October 2003 and
January 2004, a clopidogrel-free window in the prior 6 months,
and at least 24 months of continuous eligibility over the study
time-frame. ICD9 codes were used to identify new peptic ulcer
and gastrointestinal bleeding events in the 12 months after the
ﬁrst clopidogrel prescription. RESULTS: There were 368,061
subjects identiﬁed who met the selection criteria. Of these sub-
jects, 58% were male and 72% were greater than or equal to 60
years of age. The average duration of clopidogrel use was 200
days. The proportion having a medical claim for peptic ulcer or
gastrointestinal bleeding was 6.2%. Higher incidences were seen
in women compared to men (7.4% vs. 5.4%; p < 0.000001) and
those who were greater than or equal to 60 years of age
compared to those under 60 (6.9% vs. 4.3%; p < 0.000001).
CONCLUSION: There is a high incidence of medical claims for
peptic ulcer or upper gastrointestinal bleeding among patients
who receive clopidogrel, especially in women and those who are
greater than or equal to 60 years of age.
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ASSESSMENT OF SAFETY FOR BROMOCRIPTINE:
COMPARISONS OF REPORTING SYSTEMS AND A
RETROSPECTIVE COHORT STUDY
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OBJECTIVE: Because of recent attention to public adverse event
reporting systems, we assessed ﬁndings from published case
reports and adverse drug reactions reported to the World Health
Organization (WHO) Programme for International Drug
Monitoring and ﬁndings from an analysis of patients in the
General Practice Research Database (GPRD) regarding bro-
mocriptine and risk of myocardial infarction and stroke (CVD).
METHODS: We tallied reports of adverse CVD events related to
bromocriptine in the medical literature using PubMed (years
A192 Abstracts
